16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.
NICE have published a positive final appraisal document recommending routine NHS use of Venclyxto (venetoclax) with azacitidine for the treatment of aggressive blood cancer acute myeloid leukaemia.